Advanced search
Publication Cover
Future Medicinal Chemistry Volume 11, 2019 - Issue 19
Submit an article Journal homepage
5,616
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A Structure-Guided Molecular Chaperone Approach for Restoring the Transcriptional Activity of the p53 Cancer Mutant Y220C

Matthias R Bauer1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK
,
Rhiannon N Jones2 Department of ChemistrySchool of Life SciencesUniversity of SussexFalmerBrightonEast SussexBN1 9QJUK
,
Raysa K Tareque2 Department of ChemistrySchool of Life SciencesUniversity of SussexFalmerBrightonEast SussexBN1 9QJUK
,
Bradley Springett2 Department of ChemistrySchool of Life SciencesUniversity of SussexFalmerBrightonEast SussexBN1 9QJUK
,
Felix A Dingler1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK
,
Lorena Verduci1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK
,
Ketan J Patel1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK
,
Alan R Fersht1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK
,
Andreas C Joerger1 MRC Laboratory of Molecular BiologyFrancis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0QHUK;3 Institute of Pharmaceutical ChemistryJohann Wolfgang Goethe UniversityMax-von-Laue-Str. 960438Frankfurt am MainGermany;4 Buchmann Institute for Molecular Life Sciences & Structural Genomics Consortium (SGC)Max-von-Laue-Str. 1560438Frankfurt am MainGermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1232-0138
ORCID Icon &
John Spencer2 Department of ChemistrySchool of Life SciencesUniversity of SussexFalmerBrightonEast SussexBN1 9QJUKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5231-8836
ORCID Icon show all
Pages 2491-2504 | Received 06 Jun 2019, Accepted 02 Aug 2019, Published online: 21 Oct 2019

References

  • Joerger AC , FershtAR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem.85, 375–404 (2016).
  • Vousden KH , PrivesC. Blinded by the light: the growing complexity of p53. Cell137, 413–431 (2009).
  • Bieging KT , MelloSS, AttardiLD. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer14, 359–370 (2014).
  • Khoo KH , VermaCS, LaneDP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov.13, 217–236 (2014).
  • Bouaoun L , SonkinD, ArdinMet al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat.37, 865–876 (2016).
  • Leroy B , FournierJL, IshiokaCet al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res.41, D962–D969 (2013).
  • Joerger AC , FershtAR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene26, 2226–2242 (2007).
  • Cho Y , GorinaS, JeffreyPD, PavletichNP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science265, 346–355 (1994).
  • Eldar A , RozenbergH, Diskin-PosnerY, RohsR, ShakkedZ. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res.41, 8748–8759 (2013).
  • Bullock AN , HenckelJ, FershtAR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene19, 1245–1256 (2000).
  • Wang G , FershtAR. Multisite aggregation of p53 and implications for drug rescue. Proc. Natl Acad. Sci. USA114, E2634–E2643 (2017).
  • Di Como CJ , PrivesC. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene16, 2527–2539 (1998).
  • Dearth LR , QianH, WangTet al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis28, 289–298 (2007).
  • Wassman CD , BaronioR, DemirOet al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat. Commun.4, 1407 (2013).
  • Joerger AC , AngHC, FershtAR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl Acad. Sci. USA103, 15056–15061 (2006).
  • Joerger AC , BauerMR, WilckenRet al. Exploiting transient protein states for the design of small-molecule stabilizers of mutant p53. Structure23, 2246–2255 (2015).
  • Lambert JM , GorzovP, VeprintsevDBet al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell15, 376–388 (2009).
  • Bykov VJ , ZhangQ, ZhangM, CederS, AbrahmsenL, WimanKG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front. Oncol.6, 21 (2016).
  • Bauer MR , JoergerAC, FershtAR. 2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells. Proc. Natl Acad. Sci. USA113, E5271–E5280 (2016).
  • Blanden AR , YuX, WolfeAJet al. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol. Pharmacol.87, 825–831 (2015).
  • Miller JJ , OrvainC, JoziSet al. Multifunctional compounds for activation of the p53-Y220C mutant in cancer. Chemistry24, 17734–17742 (2018).
  • Boeckler FM , JoergerAC, JaggiG, RutherfordTJ, VeprintsevDB, FershtAR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA105, 10360–10365 (2008).
  • Basse N , KaarJL, SettanniG, JoergerAC, RutherfordTJ, FershtAR. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem. Biol.17, 46–56 (2010).
  • Wilcken R , LiuX, ZimmermannMOet al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J. Am. Chem. Soc.134, 6810–6818 (2012).
  • Liu X , WilckenR, JoergerACet al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res.41, 6034–6044 (2013).
  • Wilcken R , ZimmermannMO, BauerMRet al. Experimental and theoretical evaluation of the ethynyl moiety as a halogen bioisostere. ACS Chem. Biol.10, 2725–2732 (2015).
  • Bauer MR , JonesRN, BaudMGet al. Harnessing fluorine-sulfur contacts and multipolar interactions for the design of p53 mutant Y220C rescue drugs. ACS Chem. Biol.11, 2265–2274 (2016).
  • Baud MGJ , BauerMR, VerduciLet al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. Eur. J. Med. Chem.152, 101–114 (2018).
  • Rennison D , GueretSM, LaitaOet al. Substituted carbazoles – a new class of anthelmintic agent. Aust. J. Chem.69, 1268–1276 (2016).
  • Wilcken R , WangG, BoecklerFM, FershtAR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc. Natl Acad. Sci. USA109, 13584–13589 (2012).
  • Wang H , LaRussa M, QiLS. CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem.85, 227–264 (2016).
  • Kabsch W . XDS. Acta Crystallogr. D66, 125–132 (2010).
  • Evans P . Scaling and assessment of data quality. Acta Crystallogr. D62, 72–82 (2006).
  • Winn MD , BallardCC, CowtanKDet al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D67, 235–242 (2011).
  • Adams PD , AfoninePV, BunkocziGet al. PHENIX: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr. D66, 213–221 (2010).
  • Emsley P , LohkampB, ScottWG, CowtanK. Features and development of coot. Acta Crystallogr. D66, 486–501 (2010).
  • Xu J , ReumersJ, CouceiroJRet al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol.7, 285–295 (2011).
  • Wang G , FershtAR. Propagation of aggregated p53: cross-reaction and coaggregation vs. seeding. Proc. Natl Acad. Sci. USA112, 2443–2448 (2015).
  • Aschauer L , MullerPA. Novel targets and interaction partners of mutant p53 gain-of-function. Biochem. Soc. Trans.44, 460–466 (2016).
  • Kehrloesser S , OsterburgC, TuppiM, SchaferB, VousdenKH, DotschV. Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family. Cell Death Differ.23, 1952–1960 (2016).
  • Wilcken R , ZimmermannMO, LangeA, JoergerAC, BoecklerFM. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem.56, 1363–1388 (2013).
  • Zhang X , GongZ, LiJ, LuT. Intermolecular sulfur…oxygen interactions: theoretical and statistical investigations. J. Chem. Inf. Model.55, 2138–2153 (2015).
  • Fischer M . Census and evaluation of p53 target genes. Oncogene36, 3943–3956 (2017).
  • Harford TJ , KlimentG, ShuklaGC, WeymanCM. The muscle regulatory transcription factor MyoD participates with p53 to directly increase the expression of the pro-apoptotic Bcl2 family member PUMA. Apoptosis22, 1532–1542 (2017).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.